Neurocrine Biosciences (NBIX) Misses Q1 EPS by 114c; misses on guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $142.70 -0.41%
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +30.8%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.51), $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410 million versus the consensus estimate of $410.82 million.
GUIDANCE:
Neurocrine Biosciences sees FY2023 revenue of $1.67-1.77 billion, versus the consensus of $1.81 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Wells Fargo Names Top Pick Ahead of Q3 Earnings
- Accenture shares fall on insider sales and analyst downgrade
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
